Ketamine and Epigenetics: How Ketamine May Alter Gene Expression

Ketamine and epigenetics is an emerging research area that looks at how ketamine's antidepressant effects can last for days or weeks even though the drug clears the bloodstream within hours. Ketamine has a plasma half-life of about 2 to 3 hours, yet a single infusion can improve depression symptoms for a week or longer. Enhanced neuroplasticity and synaptogenesis explain part of this gap, but researchers increasingly point to epigenetics, the study of changes in gene expression that occur without altering the underlying DNA sequence, as another piece of the puzzle. Epigenetic modifications can switch genes on or off, amplify or silence their activity, and create lasting changes in cell behavior long after the original trigger is gone. If ketamine changes gene expression patterns in neurons through these mechanisms, that could help explain how one infusion produces effects that outlast the drug itself.

What Is Epigenetics?

Every cell in the body carries the same DNA sequence, yet a neuron behaves very differently from a liver cell or a skin cell. Epigenetic mechanisms control which genes are actively expressed in a given cell type and under what conditions. Epigenetics refers to heritable, and sometimes reversible, changes in gene activity that do not involve any change to the DNA nucleotide sequence itself.

Three epigenetic mechanisms are most relevant to ketamine research.

Histone modification

DNA in the cell nucleus wraps around protein spools called histones. Chemical changes to histones, including acetylation, methylation, phosphorylation, and ubiquitination, alter how tightly DNA is packaged and whether nearby genes can be transcribed. Histone acetylation generally opens chromatin and promotes gene expression, while histone deacetylation compacts chromatin and silences it. The balance between histone acetyltransferases (HATs) and histone deacetylases (HDACs) sets the acetylation state, and with it, how active nearby genes are.

DNA methylation

Adding methyl groups to cytosine bases in DNA, typically at CpG sites, generally suppresses gene transcription. DNA methyltransferases (DNMTs) establish and maintain these methylation patterns, and ten-eleven translocation (TET) enzymes can reverse them. Abnormal DNA methylation patterns have been linked to depression and other psychiatric disorders.

Non-coding RNA

MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) regulate gene expression after transcription by binding to messenger RNA and either degrading it or blocking its translation into protein. Changes in non-coding RNA profiles have been associated with stress, depression, and antidepressant response. According to the National Human Genome Research Institute, epigenetics describes how cells read and use genes without changing the DNA sequence itself.

Epigenetic Dysregulation in Depression

Understanding how epigenetic mechanisms go wrong in depression helps explain why ketamine's effect on gene expression matters. Chronic stress, the most consistent environmental risk factor for depression, produces widespread epigenetic changes in the brain, including:

• Increased HDAC expression in the hippocampus and prefrontal cortex, which reduces histone acetylation and suppresses genes involved in neuroplasticity and stress resilience
• Altered DNA methylation at promoter regions of genes encoding BDNF, glucocorticoid receptors, and other proteins critical for mood regulation
• Dysregulated miRNA profiles that may impair synaptic plasticity and neurotransmitter signaling

BDNF, a growth factor central to how ketamine works in the brain, is especially sensitive to epigenetic regulation. The BDNF gene has multiple promoter regions, and chronic stress increases DNA methylation at several of them, particularly promoter IV, which reduces BDNF transcription. Lower BDNF expression has been consistently linked to depression severity and treatment resistance. According to the National Institute of Mental Health, depression is one of the most common mental health conditions affecting adults in the United States.

Ketamine's Epigenetic Effects

Histone acetylation changes

Preclinical studies show that ketamine alters histone acetylation patterns in brain regions implicated in depression:

• Increased histone H3 acetylation at BDNF promoter regions in the hippocampus and prefrontal cortex, reversing the stress-induced deacetylation that suppresses BDNF expression
• Possible HDAC inhibition: some evidence suggests ketamine or its metabolites may directly or indirectly inhibit specific histone deacetylases, shifting the acetylation balance toward a more open, transcriptionally active chromatin state
• A rapid timecourse: histone acetylation changes have been observed within hours of ketamine administration, consistent with the drug's fast onset

These findings suggest ketamine may reopen genes that chronic stress has epigenetically silenced, restoring proteins needed for synaptic plasticity and stress resilience, including the synaptogenesis process that supports new synapse formation.

DNA methylation modifications

Ketamine has also been shown to alter DNA methylation at specific genomic locations in animal studies:

• BDNF promoter demethylation: animal studies report that ketamine reduces DNA methylation at BDNF gene promoters, increasing BDNF transcription. This matters because it represents a more durable change than simply raising BDNF protein levels; it alters the underlying instructions that govern how much BDNF a cell produces over time.
• Glucocorticoid receptor gene changes: shifts in methylation at the NR3C1 gene, which encodes the glucocorticoid receptor, may alter hypothalamic-pituitary-adrenal (HPA) axis sensitivity and potentially normalize the stress response dysregulation seen in depression.
• Global methylation patterns: genome-wide methylation studies in animal models suggest ketamine affects methylation at hundreds of genomic sites, many linked to synaptic function, immune signaling, and circadian regulation.

MicroRNA changes

Emerging animal research also points to ketamine-induced changes in specific microRNAs:

• miR-206, which normally suppresses BDNF expression, has been found to decrease after ketamine administration, possibly contributing to BDNF upregulation through a separate post-transcriptional pathway
• miR-132, involved in dendritic growth and synaptic plasticity, has been reported to increase after ketamine treatment, consistent with the drug's pro-synaptogenic effects
• miR-124, implicated in microglial activation and neuroinflammation, may change in ways that help explain some of ketamine's anti-inflammatory effects

This model suggests ketamine's antidepressant effect starts with a short-lived pharmacological trigger that sets off durable biological changes, a different mechanism from SSRIs and other conventional antidepressants that need continuous drug presence to keep receptors occupied.

Implications for Repeated Dosing

If epigenetic changes partly drive ketamine's therapeutic effects, repeated dosing may produce cumulative epigenetic modifications that become more stable over time. This could help explain why some patients report longer-lasting responses after a series of treatments than after a single infusion, a pattern discussed further in this guide to ketamine treatment methods. It also raises the possibility that a well-timed treatment course could produce epigenetic changes durable enough to sustain remission without ongoing maintenance treatment, though this remains speculative and unproven in humans.

Enantiomer-Specific Epigenetic Effects

Ketamine's two mirror-image molecules, esketamine and arketamine (also called R-ketamine), may differ in their epigenetic effects. Preclinical data suggests arketamine may produce stronger, longer-lasting epigenetic changes at BDNF promoter regions than esketamine, which could contribute to its longer-lasting antidepressant-like effects seen in animal models. Readers comparing racemic ketamine and esketamine (Spravato) may find this an active area worth watching as next-generation ketamine-based therapies develop.

Future Directions

Researchers are working to close several gaps in this evidence base:

• Human postmortem and peripheral biomarker studies comparing epigenetic profiles of ketamine responders and non-responders
• Single-cell epigenomics to identify which specific brain cell types undergo ketamine-induced epigenetic changes
• Longitudinal studies tracking epigenetic marks across multiple treatment sessions to see whether cumulative changes correlate with treatment durability
• Combination studies pairing ketamine with epigenetic-modifying agents, such as HDAC inhibitors, to test whether epigenetic enhancement improves antidepressant response
• Research into whether ketamine-induced epigenetic changes could be transmitted to offspring, as has been shown with other environmental exposures

Summary

Epigenetics offers a plausible explanation for how ketamine produces a lasting antidepressant effect from a brief drug exposure. By altering histone acetylation, DNA methylation, and microRNA expression, particularly at genes tied to neuroplasticity and stress resilience, ketamine may reshape gene expression patterns in ways that outlast the drug's presence in the bloodstream. The evidence remains mostly preclinical, but this perspective helps explain ketamine's distinct clinical profile and points toward how next-generation treatments might be designed.